SecBot SecBot
PRESS-RELEASE ·Filed Mar 24, 2026

TELA

TELA Bio, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Await full 8-K or earnings call for actual financial performance details. Lack of disclosed metrics suggests possible weakness or strategic omission.

DirectionNeutral
Confidencelow
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.6900
T+0 close · Mar 24, 2026 · via day close
Latest settled
+19.57%
T+60 · $0.8250
Vs SPY
+6.11%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 25 $0.6900entry
  2. T+1 · 8mo ago +8.12%α +9.89% · $0.7460
  3. T+5 · 8mo ago −17.54%α −17.29% · $0.5690
  4. T+20 · 7mo ago −9.86%α −17.72% · $0.6220
  5. T+60 · 5mo ago +19.57%α +6.11% · $0.8250
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

TELA Bio reported financial results for Q4 and full year 2025. The press release announces earnings but contains no actual financial figures such as revenue, EPS, or guidance, limiting actionable insights.

Key Facts

  • TELA Bio released financial results for Q4 and full year 2025.
  • No quantitative financial data (revenue, EPS, margins, guidance) was disclosed in the provided text.
  • Company described as commercial-stage with focus on soft-tissue reconstruction solutions.

Financial Impact

Insufficient data to determine financial impact

Risk Factors

  • Material financial figures not disclosed in press release, raising transparency concerns.
  • Potential for negative market reaction if results were materially weak.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3261734

Track record

20 reports on TELA

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +18.61% at T+5 after the Aug 10, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $0.7610 Now $0.7620 +0.13% settles Nov 23
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.8200 Now $0.7620 −7.07% settles Nov 23
  3. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $0.8201 Now $0.7620 −7.08% settles Nov 23
  4. Nov 10, 20266d ago S-3 Bearish 5/10 Entry $0.9418 Now $0.7620 +19.09% settles Nov 18
  5. Nov 10, 20266d ago Press Release Bearish 5/10 Entry $0.9418 Now $0.7620 +19.09% settles Nov 18
  6. Oct 27, 202620d ago Press Release Neutral 2/10 Entry $0.9760 to $0.8378 Now $0.7620 −21.93% ▼ −14.16% −13.45% vs SPY
  7. Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.07 to $1.10 Now $0.7620 −28.79% ▲ +2.34% +3.32% vs SPY
  8. Oct 5, 20266w ago 8-K Bullish 5/10 Entry $1.14 to $1.08 Now $0.7620 −33.16% ▼ −5.26% −5.69% vs SPY
  9. Aug 31, 202611w ago 8-K Mixed 6/10 Entry $0.7380 to $0.8301 Now $0.7620 +3.25% ▲ +12.48% +12.62% vs SPY
  10. Aug 10, 202614w ago 8-K Bearish 7/10 Entry $0.7900 to $0.6430 Now $0.7620 +3.54% ▲ +18.61% +18.20% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 24, 2026